Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,689 result(s) found for: placebo. Displaying page 242 of 635.
    «« First « Previous 238  239  240  241  242  243  244  245  246  Next» Last»»
    EudraCT Number: 2009-017971-10 Sponsor Protocol Number: P05896 Start Date*: 2011-10-12
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: An 8-week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety trial of asenapine in adolescent subjects with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002449-40 Sponsor Protocol Number: P057-00 Start Date*: 2012-10-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 μg nomegestrol...
    Medical condition: This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NO (Completed) NL (Completed) BE (Completed) SE (Completed) PL (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000651-13 Sponsor Protocol Number: 20120102 Start Date*: 2012-06-27
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000414-11 Sponsor Protocol Number: 603-PG-PSC-191 Start Date*: 2012-08-31
    Sponsor Name:LETI Pharma GmbH
    Full Title: Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) FI (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-004450-15 Sponsor Protocol Number: RPL554-CO-202 Start Date*: 2017-01-27
    Sponsor Name:Verona Pharma plc
    Full Title: A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003863-31 Sponsor Protocol Number: EFC10438 Start Date*: 2008-04-25
    Sponsor Name:Sanofi-Aventis recherche & développement
    Full Title: An eight-week, double-blind study to evaluate the efficacy, safety, and tolerability of two fixed doses of saredutant (100 mg and 30 mg) once daily in combination with paroxetine 20 mg once daily c...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001972-70 Sponsor Protocol Number: PII116678 Start Date*: 2015-05-04
    Sponsor Name:GlaxoSmithKline Reasearch & Development
    Full Title: A randomised, double-blind (sponsor unblinded), placebocontrolled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care i...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-005381-39 Sponsor Protocol Number: A5051017 Start Date*: 2007-06-07
    Sponsor Name:Pfizer Ltd, Ramsgate Road, Sandwich, Kent. UK
    Full Title: A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROU...
    Medical condition: Female Sexual Dysfunction (FSD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062641 Female sexual arousal disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003516-62 Sponsor Protocol Number: CYT003-QbG10 08 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002055-32 Sponsor Protocol Number: PSD506-OAB-004 Start Date*: 2006-10-09
    Sponsor Name:Plethora Solutions Limited
    Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct...
    Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055026 Prostatic obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023228-26 Sponsor Protocol Number: TZP-101-CL-P007 Start Date*: 2011-02-18
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastroin...
    Medical condition: post-operative ileus in subjects who have undergone partial bowel resection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054048 Postoperative ileus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000228-52 Sponsor Protocol Number: P-110881-01 Start Date*: 2014-06-03
    Sponsor Name:Ferrer Internacional, SA
    Full Title: A phase III 2 arms, multicenter, randomised, double-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients w...
    Medical condition: Impetigo
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008593-31 Sponsor Protocol Number: 2PX-OA-03 Start Date*: 2009-04-03
    Sponsor Name:SantoSolve A/S
    Full Title: A 26 week placebo-controlled, randomised, double-blind, parallel group study of the efficacy and safety of 2PX (topical strontium chloride hexahydrate) in patients with pain due to osteoarthritis o...
    Medical condition: pain associated with osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031161 Osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000107-40 Sponsor Protocol Number: GRC4039-203 Start Date*: 2011-06-16
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumato...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001063-12 Sponsor Protocol Number: EVB-003 Start Date*: 2015-04-22
    Sponsor Name:Evolus Inc.
    Full Title: A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-s...
    Medical condition: moderate-to-severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004374-90 Sponsor Protocol Number: D6160C00055 Start Date*: 2005-04-01
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered as Monotherapy...
    Medical condition: Men or women who are 18 years of age or more at enrolment (visit 1). The patients should be drug-naïve with Type 2 diabetes and not on anti-diabetic treatment during the recent 24 weeks.
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003753-26 Sponsor Protocol Number: GS-US-324-0101 Start Date*: 2012-05-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001728-30 Sponsor Protocol Number: MPEX-204 Start Date*: 2008-08-26
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP- 376 Solution for Inhalation Given for 2...
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000976-26 Sponsor Protocol Number: CV181-066 Start Date*: 2008-08-10
    Sponsor Name:BRISTOL-M.SQUIBB
    Full Title: A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in ...
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005316-28 Sponsor Protocol Number: CBGG492A2214 Start Date*: 2012-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492...
    Medical condition: Non-chronic migraine with or without aura
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 238  239  240  241  242  243  244  245  246  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:19:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA